TY - JOUR
T1 - Both HIV-Infected and uninfected cells express TRAILshort, which confers TRAIL resistance upon bystander cells within the microenvironment
AU - Nie, Zilin
AU - Aboulnasr, Fatma
AU - Natesampillai, Sekar
AU - Burke, Stephen P.
AU - Krogman, Ashton
AU - Bren, Gary D.
AU - Chung, Thomas D.Y.
AU - Anderson, Jeff R.
AU - Smart, Michele K.
AU - Katzmann, David J.
AU - Rajagopalan, Govindarajan
AU - Cummins, Nathan W.
AU - Badley, Andrew D.
N1 - Funding Information:
This work was supported by National Institutes of Health Grants R01AI110173 and R01AI120698 to A.D.B. and through Clinician Investigator support from the Mayo Clinic and Foundation.
Publisher Copyright:
Copyright © 2018 by The American Association of Immunologists, Inc.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
AB - TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
UR - http://www.scopus.com/inward/record.url?scp=85044744989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044744989&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1701113
DO - 10.4049/jimmunol.1701113
M3 - Article
C2 - 29263214
AN - SCOPUS:85044744989
SN - 0022-1767
VL - 200
SP - 1110
EP - 1123
JO - Journal of Immunology
JF - Journal of Immunology
IS - 3
ER -